KR102637610B1 - 단백질용해 절단가능한 키메라 폴리펩타이드 및 이의 사용 방법 - Google Patents

단백질용해 절단가능한 키메라 폴리펩타이드 및 이의 사용 방법 Download PDF

Info

Publication number
KR102637610B1
KR102637610B1 KR1020237006942A KR20237006942A KR102637610B1 KR 102637610 B1 KR102637610 B1 KR 102637610B1 KR 1020237006942 A KR1020237006942 A KR 1020237006942A KR 20237006942 A KR20237006942 A KR 20237006942A KR 102637610 B1 KR102637610 B1 KR 102637610B1
Authority
KR
South Korea
Prior art keywords
delete delete
polypeptide
cell
cases
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237006942A
Other languages
English (en)
Korean (ko)
Other versions
KR20230038295A (ko
Inventor
웬델 에이. 림
콜 티. 로이발
제스퍼 제트. 윌리엄스
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 filed Critical 더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Publication of KR20230038295A publication Critical patent/KR20230038295A/ko
Application granted granted Critical
Publication of KR102637610B1 publication Critical patent/KR102637610B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4213—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C07K2319/715—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16 containing a domain for ligand dependent transcriptional activation, e.g. containing a steroid receptor domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developmental Biology & Embryology (AREA)
KR1020237006942A 2016-08-23 2017-08-22 단백질용해 절단가능한 키메라 폴리펩타이드 및 이의 사용 방법 Active KR102637610B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662378614P 2016-08-23 2016-08-23
US62/378,614 2016-08-23
PCT/US2017/048040 WO2018039247A1 (en) 2016-08-23 2017-08-22 Proteolytically cleavable chimeric polypeptides and methods of use thereof
KR1020197005928A KR20190051956A (ko) 2016-08-23 2017-08-22 단백질용해 절단가능한 키메라 폴리펩타이드 및 이의 사용 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197005928A Division KR20190051956A (ko) 2016-08-23 2017-08-22 단백질용해 절단가능한 키메라 폴리펩타이드 및 이의 사용 방법

Publications (2)

Publication Number Publication Date
KR20230038295A KR20230038295A (ko) 2023-03-17
KR102637610B1 true KR102637610B1 (ko) 2024-02-19

Family

ID=61245300

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237006942A Active KR102637610B1 (ko) 2016-08-23 2017-08-22 단백질용해 절단가능한 키메라 폴리펩타이드 및 이의 사용 방법
KR1020197005928A Ceased KR20190051956A (ko) 2016-08-23 2017-08-22 단백질용해 절단가능한 키메라 폴리펩타이드 및 이의 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197005928A Ceased KR20190051956A (ko) 2016-08-23 2017-08-22 단백질용해 절단가능한 키메라 폴리펩타이드 및 이의 사용 방법

Country Status (9)

Country Link
US (3) US11401332B2 (https=)
EP (1) EP3504245A4 (https=)
JP (2) JP7500195B2 (https=)
KR (2) KR102637610B1 (https=)
CN (1) CN109843929B (https=)
AU (1) AU2017316649A1 (https=)
CA (1) CA3034093A1 (https=)
SG (2) SG10201913583QA (https=)
WO (1) WO2018039247A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013540757A (ja) 2010-09-24 2013-11-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド カプセル化された作用物質の放出を制御する能力を有するナノ構造ゲル
CN107530424A (zh) 2015-02-20 2018-01-02 俄亥俄州国家创新基金会 针对nkg2d和肿瘤相关抗原的二价抗体
AU2016246457B2 (en) 2015-04-06 2020-10-15 Cytoimmune Therapeutics, Inc. EGFR-directed car therapy for glioblastoma
CN110225760B (zh) * 2016-09-15 2023-11-07 埃里西拉医疗公司 T细胞免疫疗法
MX2019003462A (es) * 2016-09-28 2019-08-16 Gavish Galilee Bio Appl Ltd Una plataforma universal para el tratamiento con car que se dirige a una novedosa firma antigenica del cancer.
WO2018144991A1 (en) 2017-02-03 2018-08-09 The Brigham And Women's Hospital, Inc. Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
US11807662B2 (en) * 2017-05-16 2023-11-07 The Johns Hopkins University MANAbodies and methods of using
US11325957B2 (en) * 2017-06-19 2022-05-10 Cell Design Labs, Inc. Methods and compositions for reducing the immunogenicity of chimeric notch receptors
CA3092355A1 (en) * 2018-03-16 2019-09-19 Cytoimmune Therapeutics, Inc. Bispecific antibody car cell immunotherapy
GB201804291D0 (en) * 2018-03-16 2018-05-02 Evox Therapeutics Ltd Cell-mediated exosome delivery
JP2021520352A (ja) 2018-04-04 2021-08-19 アリヴィオ セラピューティクス， インコーポレイテッド 生物製剤の制御送達用の自己組織化ゲルおよびその製造方法
AU2019247830B2 (en) * 2018-04-06 2026-02-19 The Regents Of The University Of California Trans-antigen targeting in heterogeneous cancers and methods of use thereof
CA3096202A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
CA3095757A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating glioblastomas
AU2019252878B2 (en) * 2018-04-10 2024-02-22 Stichting Sanquin Bloedvoorziening Chimeric Notch receptors
US20210317479A1 (en) 2018-09-06 2021-10-14 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
US12466892B2 (en) 2018-11-08 2025-11-11 The Regents Of The University Of California Systems and methods for targeting cancer cells
CA3121911A1 (en) * 2018-12-06 2020-06-11 The Board Of Trustees Of The Leland Stanford Junior University Regulatable cell surface receptors and related compositions and methods
CN113164578B (zh) * 2019-01-03 2024-04-30 南京传奇生物科技有限公司 表达鞭毛蛋白多肽的经修饰的免疫细胞
JP7739261B2 (ja) * 2019-08-09 2025-09-16 エイ２・バイオセラピューティクス・インコーポレイテッド ヘテロ接合性の喪失に応答する細胞表面受容体
CN114729025A (zh) * 2019-09-24 2022-07-08 加利福尼亚大学董事会 用于配体依赖性转录调控的新型受体
EP4034254A4 (en) * 2019-09-24 2023-11-01 The Regents of the University of California RECEPTORS WITH HETEROLOGUE TRANSMEMBRANE DOMAIN
CN114761084B (zh) * 2019-09-24 2023-10-27 加利福尼亚大学董事会 具有铰链结构域的Notch受体
WO2021061791A1 (en) * 2019-09-24 2021-04-01 The Regents Of The University Of California Notch receptors with zinc finger-containing transcriptional effector
CN110716044B (zh) * 2019-10-23 2023-04-18 郑州大学 一种用于食管鳞癌早期筛查和诊断的血清蛋白标志物、试剂盒及检测方法
US12195723B2 (en) 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
CN110970090B (zh) * 2019-11-18 2021-06-29 华中科技大学 一种用于判断待处理多肽与阳性数据集肽段相似度的方法
WO2021119539A1 (en) * 2019-12-12 2021-06-17 Senti Biosciences, Inc. Method and compositions for regulated armoring of cells
CN115151644B (zh) * 2019-12-27 2024-06-21 国立大学法人神户大学 癌基因治疗药
US20230183709A1 (en) * 2020-04-09 2023-06-15 The Regents Of The University Of California Humanized notch receptors with hinge domain
US20230226213A1 (en) * 2020-06-18 2023-07-20 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating cells and cellular membranes
KR102859550B1 (ko) 2020-08-20 2025-09-16 에이투 바이오쎄라퓨틱스, 인크. Ceacam 양성 암을 치료하기 위한 조성물 및 방법
WO2022040454A1 (en) 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
US20240150755A1 (en) * 2021-02-26 2024-05-09 Salk Institute For Biological Studies Modulating regulatory t cell function in autoimmune disease and cancer
AU2022244245A1 (en) * 2021-03-23 2023-10-05 The Regents Of The University Of California Synthetic intermembrane proteolysis receptors for custom antigen-induced transcriptional regulation
WO2022204326A1 (en) * 2021-03-24 2022-09-29 The Regents Of The University Of California Humanized synthetic notch receptors with augmented transactivation domains and uses thereof
CN114045272B (zh) * 2021-03-24 2024-12-06 深圳市新靶向生物科技有限公司 一种与乳腺癌驱动基因突变相关的抗原肽组合及其应用
AU2022366987A1 (en) 2021-10-14 2024-05-16 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
CN114107253B (zh) * 2021-12-17 2024-03-15 复旦大学附属华山医院 一种利用工程细胞进行基因编辑的系统及方法
CN114736308B (zh) * 2022-03-15 2022-12-27 四川宜美康科技有限公司 球虫抗原肽/il5的融合蛋白基因工程菌的制备及用途
CN117510615B (zh) * 2023-01-31 2025-01-07 上海恩凯细胞技术有限公司 SynNotch受体及其用途
WO2025076422A1 (en) * 2023-10-05 2025-04-10 The Regents Of The University Of California Regulated expression of card11-pik3r3 fusion protein

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780300A (en) 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
GB0112818D0 (en) * 2001-05-25 2001-07-18 Lorantis Ltd Conjugate
GB0220658D0 (en) 2002-09-05 2002-10-16 Lorantis Ltd Immunotherapy
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
EP2195658A2 (en) 2007-09-28 2010-06-16 Royal College of Surgeons in Ireland A method of assessing colorectal cancer status in an individual
CN104402998A (zh) 2008-07-08 2015-03-11 昂考梅德药品有限公司 分离的抗体
CA2796464C (en) 2010-04-16 2021-08-03 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
AU2013327136A1 (en) 2012-10-02 2015-04-16 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US10144770B2 (en) * 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
MX389160B (es) 2013-10-31 2025-03-20 Hutchinson Fred Cancer Res Células no t efectoras y madre/progenitoras hematopoyéticas modificadas y usos de estas.
US9730935B2 (en) 2013-12-13 2017-08-15 The Board Of Trustees Of The Leland Stanford Junior University Targeting a non-canonical notch signaling pathway for cancer treatment
ES3012974T3 (en) 2014-01-08 2025-04-10 Univ Leland Stanford Junior Targeted therapy for lung cancer
EP3656864A1 (en) 2014-02-14 2020-05-27 Board of Regents, The University of Texas System Chimeric antigen receptors and methods of making
US10196608B2 (en) 2014-02-21 2019-02-05 Cellectis Method for in situ inhibition of regulatory T cells
US20160152725A1 (en) * 2014-02-25 2016-06-02 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
ES2781175T3 (es) * 2014-07-31 2020-08-31 Novartis Ag Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
WO2016033331A1 (en) 2014-08-28 2016-03-03 Bioatla, Llc Conditionally active chimeric antigen receptors for modified t-cells
CA2959428A1 (en) * 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
WO2016093243A1 (ja) 2014-12-09 2016-06-16 北海道公立大学法人札幌医科大学 腫瘍抗原ペプチド
WO2016138034A1 (en) 2015-02-24 2016-09-01 The Regents Of The University Of California Binding-triggered transcriptional switches and methods of use thereof
WO2017193059A1 (en) 2016-05-06 2017-11-09 The Regents Of The University Of California Systems and methods for targeting cancer cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer Gene Therapy 제19권, 84-100 면 (2012)
Cell 제164권, 770-779 (2016.02.11.)

Also Published As

Publication number Publication date
KR20190051956A (ko) 2019-05-15
US11401332B2 (en) 2022-08-02
US12358988B2 (en) 2025-07-15
EP3504245A1 (en) 2019-07-03
CN109843929B (zh) 2024-07-05
SG11201901528RA (en) 2019-03-28
SG10201913583QA (en) 2020-02-27
US20250304698A1 (en) 2025-10-02
EP3504245A4 (en) 2020-04-22
US20190202918A1 (en) 2019-07-04
JP2019528077A (ja) 2019-10-10
JP7500195B2 (ja) 2024-06-17
CA3034093A1 (en) 2018-03-01
JP2022106714A (ja) 2022-07-20
US20220324982A1 (en) 2022-10-13
CN109843929A (zh) 2019-06-04
WO2018039247A1 (en) 2018-03-01
KR20230038295A (ko) 2023-03-17
AU2017316649A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
US12358988B2 (en) Proteolytically cleavable chimeric polypeptides and methods of use thereof
US12065479B2 (en) Force sensor cleavage domain containing chimeric polypeptides and methods of use thereof
TWI906906B (zh) 抗ccr8抗體及其用途
JP7759428B2 (ja) Ｃｃｒ８に結合する抗体及び融合タンパク質並びにそれらの使用
US20200345845A1 (en) Compositions and methods related to cell systems for penetrating solid tumors
JP2023015262A (ja) ヒトｃｄ１３７に結合するアゴニスト性抗体およびその使用
CN112384534A (zh) 用于增强nk细胞对靶细胞的杀死的组合物和方法
CN106163547A (zh) 使用嵌合抗原受体治疗癌症
AU2019247830B2 (en) Trans-antigen targeting in heterogeneous cancers and methods of use thereof
WO2021080682A1 (en) Monoclonal antibodies that bind human cd161 and uses thereof
US20240018248A1 (en) An ltbr agonist in combination therapy against cancer
JP2024016134A (ja) 細胞療法に関連する毒性に関する製造物品および方法
HK40008768A (zh) 蛋白水解可切割的嵌合多肽及其使用方法
HK40102183A (zh) 非阻断性人ccr8结合剂

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230227

Application number text: 1020197005928

Filing date: 20190227

PG1501 Laying open of application
E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231120

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240213

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240214

End annual number: 3

Start annual number: 1

PG1601 Publication of registration